130 related articles for article (PubMed ID: 12063682)
21. Decision-making Processes among Prostate Cancer Survivors with Rising PSA Levels: Results from a Qualitative Analysis.
Shen MJ; Nelson CJ; Peters E; Slovin SF; Hall SJ; Hall M; Herrera PC; Leventhal EA; Leventhal H; Diefenbach MA
Med Decis Making; 2015 May; 35(4):477-86. PubMed ID: 25385751
[TBL] [Abstract][Full Text] [Related]
22. [The role of PSA in diagnosis of prostate cancer and its recurrence].
Vergho DC; Heine K; Wolff JM
Pathologe; 2005 Nov; 26(6):473-8. PubMed ID: 16215709
[TBL] [Abstract][Full Text] [Related]
23. Tumor markers in advanced nonseminomatous testicular cancer.
Bosl GJ; Lange PH; Nochomovitz LE; Goldmann A; Fraley EE; Rosai J; Johnson K; Kennedy BJ
Cancer; 1981 Feb; 47(3):572-6. PubMed ID: 6164464
[TBL] [Abstract][Full Text] [Related]
24. [Metastasis and markers].
Trinchieri A; Rovera F; Longo G; Del Nero A; Zanetti G; Austoni E
Arch Ital Urol Nefrol Androl; 1992 Mar; 64(1):27-30. PubMed ID: 1373913
[TBL] [Abstract][Full Text] [Related]
25. [Tumor marker in urology].
Shimazaki J; Ito H; Miyauchi T; Maruoka M; Isaka S; Masukagami T; Ando K
Gan No Rinsho; 1983 May; 29(6):684-92. PubMed ID: 6192269
[TBL] [Abstract][Full Text] [Related]
26. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
27. [Biological markers and germinal tumors of the testis. Value and limitations of the assay of chorionic gonadotrophin hormone and alpha-fetoprotein].
Bassoulet J; Pabot du Chatelard P; Ricordel I; Auberget JL; Guillemot MC; Merrer J; Timbal Y
J Urol (Paris); 1988; 94(8):393-6. PubMed ID: 2467947
[TBL] [Abstract][Full Text] [Related]
28. Expression and significance of TSGF, CEA and AFP in patients before and after radical surgery for colon cancer.
Hu Y; Wang JL; Tao HT; Wu BS; Sun J; Cheng Y; Dong WW; Li RX
Asian Pac J Cancer Prev; 2013; 14(6):3877-80. PubMed ID: 23886200
[TBL] [Abstract][Full Text] [Related]
29. [Sense and nonsense of tumor markers in practice].
Joss R; Cerny T
Schweiz Med Wochenschr; 1990 May; 120(19):693-703. PubMed ID: 1693445
[TBL] [Abstract][Full Text] [Related]
30. A Framework for Treatment Decision Making at Prostate Cancer Recurrence.
Lange JM; Trock BJ; Gulati R; Etzioni R
Med Decis Making; 2017 Nov; 37(8):905-913. PubMed ID: 28564551
[TBL] [Abstract][Full Text] [Related]
31. Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma.
Alvarez JA; Marín J; Jover JM; Fernández R; Fradejas J; Moreno M
Dis Colon Rectum; 1995 May; 38(5):535-42. PubMed ID: 7537651
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Factors of Prostate Cancer in Tunisian Men: Immunohistochemical Study.
Missaoui N; Abdelkarim SB; Mokni M; Hmissa S
Asian Pac J Cancer Prev; 2016; 17(5):2655. PubMed ID: 27268646
[TBL] [Abstract][Full Text] [Related]
33. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.
Shirakawa T; Gotoh A; Zhang Z; Kao C; Chung LW; Gardner TA
Urology; 2004 Mar; 63(3):613-8. PubMed ID: 15028478
[TBL] [Abstract][Full Text] [Related]
34. Patients' perceptions and attitudes on recurrent prostate cancer and hormone therapy: Qualitative comparison between decision-aid and control groups.
Gorawara-Bhat R; O'Muircheartaigh S; Mohile S; Dale W
J Geriatr Oncol; 2017 Sep; 8(5):368-373. PubMed ID: 28602711
[TBL] [Abstract][Full Text] [Related]
35. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
[TBL] [Abstract][Full Text] [Related]
36. [PSA-related parameters in prostate cancer relapsed after endocrine therapy].
Nakata S; Takahashi H; Takezawa Y; Kobayashi M; Matumoto K; Kosaku N; Kawashima K
Nihon Hinyokika Gakkai Zasshi; 2002 Sep; 93(6):686-93. PubMed ID: 12385093
[TBL] [Abstract][Full Text] [Related]
37. Tumor markers in hydrocele fluids of patients with benign and malignant scrotal diseases.
Dorfinger K; Kratzik C; Madersbacher S; Dorfinger G; Berger P; Marberger M
J Urol; 1997 Sep; 158(3 Pt 1):851-5. PubMed ID: 9258097
[TBL] [Abstract][Full Text] [Related]
38. Value of five tumor markers (AFP, CEA, hCG, hPL and SP1) in diagnosis and staging of testicular germ cell tumors.
Szymendera JJ; Zborzil J; Sikorowa L; Kamińska JA; Gadek A
Oncology; 1981; 38(4):222-9. PubMed ID: 6165945
[TBL] [Abstract][Full Text] [Related]
39. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
40. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.
Barresi V; Ieni A; Cardia R; Licata L; Vitarelli E; Reggiani Bonetti L; Tuccari G
APMIS; 2016 Mar; 124(3):188-93. PubMed ID: 26590121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
